Article

Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy

2024-04-12

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Androgen deprivation therapy (ADT) is a frontline treatment for prostate cancer but often leads to the development of castration resistant prostate cancer (CRPC). This causes tumors to regrow and metastasize, despite ongoing treatment, and impacts negatively on patient survival. ADT is known to stimulate the accumulation of immunosuppressive cells like protumoral tumor-assoc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f6863ffd-943d-5b0f-9514-278c76919d66
DOI: 10.1101/2024.04.11.589003

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation TherapyDOI 10.1101/2024.04.11.589003Read

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.Semantic proximity Read

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancerSemantic proximity Read

Castration-mediated IL-8 Promotes Myeloid Infiltration and Prostate Cancer ProgressionSemantic proximity Read

PARP and PI3K inhibitor combination therapy eradicates c-MYC-driven murine prostate cancers via cGAS/STING pathway activation within tumor-associated macrophagesSemantic proximity Read

Boosting the Immune Response – Combining the Local and Immune Therapy for Prostate Cancer TreatmentSemantic proximity Read

T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapySemantic proximity Read

Activation of Stimulator of Interferon Genes (STING): Promising Strategy to Overcome Immune Resistance in Prostate CancerSemantic proximity Read

Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerSemantic proximity Read

New approaches and prospects of immunotherapy and gene therapy for prostate cancerSemantic proximity Read

CD46 targeted <sup>212</sup> Pb alpha particle radioimmunotherapy for prostate cancer treatmentSemantic proximity Read

Immunome profiling in prostate cancer: a guide for cliniciansSemantic proximity Read

A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulatorSemantic proximity Read